Trials / Recruiting
RecruitingNCT07157787
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants With PMN (Primary Membranous Nephropathy) Who Are at a High Risk for Disease Progression
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1920 | Participants will receive ALXN1920 SC infusion. |
| DRUG | Placebo | Participants will receive Placebo SC infusion. |
Timeline
- Start date
- 2025-09-19
- Primary completion
- 2027-02-12
- Completion
- 2027-02-12
- First posted
- 2025-09-05
- Last updated
- 2026-03-03
Locations
39 sites across 10 countries: United States, Argentina, Australia, Brazil, China, France, Italy, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07157787. Inclusion in this directory is not an endorsement.